![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.561, 2008-01, pp. : 1-1
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sunitinib cost-effective alternative to interferon-α in renal cancer
Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Ravasio Roberto Ortega Cinzia Sabbatini Roberto Porta Camillo
Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sunitinib cost effective for renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Chabot Isabelle Rocchi Angela
Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
First-line erlotinib maintenance cost effective in Europe
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 633, 2011-01 ,pp. :